Why Is Zebra Technologies Stock Shooting Higher Thursday?

Zebra Technologies Corp reported Q4 FY23 net sales decline of 32.9%, beating expectations. Adjusted EPS also beat with stock price rising. Zebra expects net sales to decrease in Q1 but increase for FY24.

Zebra Technologies Corp (NASDAQ:ZBRA) reported a fourth-quarter FY23 net sales decline of 32.9% year-on-year to $1.01 billion, beating the consensus of $999.36 million. 

The adjusted EPS of $1.71 beat the consensus of $1.66. The stock price moved higher after the results.

Consolidated organic net sales for the quarter decreased by 33.1% Y/Y. 

Net sales in the Enterprise Visibility & Mobility (EVM) segment fell 32.8% Y/Y to $663 million. The net sales of the Asset Intelligence and Tracking (AIT) segment decreased by 33.1% Y/Y to $346 million.

The adjusted gross margin declined by 100 bps to 44.6%, primarily due to volume deleveraging. 

The adjusted EBITDA margin declined by 710 bps to 15.4% due to the hit in gross margin and higher exit and restructuring costs.

Zebra held $137 million in cash and equivalents as of December 31, 2023.

The 2022 Productivity Plan and Voluntary Retirement Plan will likely entail charges of $130 million, up from the prior $105 million, with net annualized expense savings of $120 million, an increase from the prior $100 million.

Outlook: Zebra expects first-quarter net sales to decrease between 17% and 20 % Y/Y or $1.124 billion – $1.166 billion compared to the consensus of $1.07 billion. It sees the adjusted EPS of $2.30 – $2.60 versus the street consensus of $2.08.

Zebra expects FY24 net sales change of (1)% – 3% Y/Y or $4.538 billion – $4.722 billion compared to the consensus of $4.590 billion. 

Price Action: ZBRA shares traded higher by 13.10% at $286.01 on the last check Thursday.

Total
0
Shares
Related Posts
Read More

Invest In The Future Of Medicine Says Berner, CEO Of Cookies At Benzinga’s Psychedelics Capital Conference

Berner, the famed rapper, co-founder and CEO of the highly successful cannabis and clothing brand, Cookies, was one of the main speakers at Benzinga's Psychedelics Capital Conference last April at the Fontainebleau Miami Beach Hotel.

GAEGF

Read More

cbdMD Reports YoY Dip In Q1 Net Sales, Shrinks Operating Loss, Expands Into Hemp And Mushroom Products Markets

Medical cannabis company cbdMD has reported financial results for its first quarter of fiscal 2024. Operating loss improved to $1.1m compared to $4.1m for the same period in the previous year. Gross profit was flat at around $3.5m, while operating expenses were $4.6m, down from $7.6m in the previous year. Total net sales declined to $5.37m from almost $6m in the corresponding prior-year period. Direct-to-consumer net sales represented 82.3% of total net sales, a decrease from 90% in Q1 2023. On 31 December 2023, cbdMD had total working capital of roughly $1.4m compared to approximately $3.4m on 30 September, with cash on hand dropping to roughly $1.5m from $1.8m over the same period. The Charlotte-based company recently struck a securities purchase agreement with five institutional investors to fund the national rollout of its ATRx Labs functional mushroom products, as well as launching the hempMD and ATRx Labs brands.

YCBD